SuperworthCaris Life Sciences EPS CAI
Diluted earnings per share by quarter and over the last twelve months, from 2024.
- Last 12 months, to Jun 30, 2026
- $0.37
- Latest quarter, Q2 FY26
- $0.00
- Fiscal year 2025
- −$11.17
Caris Life Sciences' earnings per share was $0.37 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.00.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$11.17 | n/a |
| FY2024 | −$10.67 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.00 | n/a | $0.37 | |
| Q1 FY26 | $0.00 | n/a | −$7.60 | |
| Q4 FY25 | $0.29 | n/a | −$11.17 | |
| Q3 FY25 | $0.08 | n/a | −$13.20 | |
| Q2 FY25 | −$7.97 | n/a | −$15.87 | |
| Q1 FY25 | −$3.57 | n/a | −$10.44 | |
| Q4 FY24 | −$1.74 | n/a | −$10.67 | |
| Q3 FY24 | −$2.59 | n/a | n/a | |
| Q2 FY24 | −$2.54 | n/a | n/a | |
| Q1 FY24 | −$3.80 | n/a | n/a |
Against its peers
Companies in Medical - Diagnostics & Research nearest Caris Life Sciences' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CAICaris Life Sciences | $0.37 | |
| BIOBio-Rad Laboratories | $8.25 | −30% a year |
| LNTHLantheus | $4.13 | +10% a year |
| BLLNBillionToOne | $0.65 | |
| RVTYRevvity | $2.10 | −11% a year |
| MEDPMedpace | $17.05 | +27% a year |
| VCYTVeracyte | $1.40 | +324% a year |
| CDNACareDx | $2.07 | +116% a year |
| LHLabcorp | $12.09 | +33% a year |
| DGXQuest Diagnostics | $9.41 | +18% a year |
| MTDMettler-Toledo International | $44.42 | +12% a year |
| Peer median | $6.19 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Caris Life Sciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.